Table 1 Summary of clinical data
Case no. | Patient 1 | Patient 2 | Patient 3 |
|---|---|---|---|
Age | 72 | 64 | 56 |
Gender | Male | Female | Female |
Initial referring diagnosis | MDS-RAEB-2 for <1 month | CMML <3 months | Pancytopenia/thrombocytopenia for one week |
Final diagnosis at disease progression | AML | AMML | AML |
WBC (× 109/L) | 2.4 | 8.9 | 1.6 |
Hb (g/dL) | 8.5 | 11.8 | 8.2 |
Platelets (× 109/L) | 110 | 242 | 41 |
MCV (fl) | 109 | 112 | 99 |
Neutrophil percent (%) | 45 | 44 | 5.6 |
Lymphocyte percent (%) | 50 | 22 | 90.8 |
Monocyte percent (%) | 4 | 33 | 1.8 |
BM blasts % | 28 | 23 | 54 |
Follow up (months) | 4 | 3 | 3.5 |
Treatment | ara-C, imatinib vorinostat | decitabine | idarubicin, cytarabin |
Complete Remission (CR) | no | no | morphological |
Stem cell transplant | no | no | no |
Overall survival (months) | 23 | 12 | 5 |